How many drugs treat Restless legs?

Drug Landscape tracks 7 marketed treatments for Restless legs (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/restless-legs.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Restless legs — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Restless legs (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Restless legs, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Horizant	GABAPENTIN ENACARBIL	Azurity	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	2011-01-01
Neupro	ROTIGOTINE	UCB	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Requip	Requip	Boehringer Ingelheim		D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A
Requip	ropinirole	GSK		D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A
gabapentine	gabapentine	Dominik Irnich		Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor
Horizant	Horizant	University of Missouri-Columbia		Voltage-dependent calcium channel subunit alpha-2/delta-1, Voltage-dependent calcium channel subunit alpha-2/delta-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Azurity · 1 drug in Restless legs
Boehringer Ingelheim · 1 drug in Restless legs
Dominik Irnich · 1 drug in Restless legs
GSK · 1 drug in Restless legs
Generic (originally Parke-Davis/Pfizer) · 1 drug in Restless legs
UCB · 1 drug in Restless legs
University of Missouri-Columbia · 1 drug in Restless legs

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Restless legs:

Cite this brief

Drug Landscape (2026). Restless legs — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/restless-legs. Accessed 2026-06-10.

Restless legs full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing